Freeline is a leading clinical-stage biotechnology company. We focus on development and commercialisation of innovative gene therapies to change lives.
Our ambitious vision is to create better lives for people suffering from chronic, debilitating disease. We are developing functional cures for a wide range of liver-based diseases which have previously been underserved and incurable.
Our next generation gene therapy uses AAV technology to deliver safe and effective gene replacement to the liver to produce sustained therapeutic protein expression for diseases like haemophilia B and Fabry.
We will use our novel proprietary capsid across our entire pipeline, leveraging faster and cost effective pathways to clinic for our different indications. We are working hard on our vision to build and advance a pipeline of curative treatments to make a life-changing impact.